- Home
- MPU vs MURA Comparison
MPU vs MURA Comparison
Compare MPU & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- MURA
- Stock Information
- Founded
- MPU 1989
- MURA 2013
- Country
- MPU Singapore
- MURA Ireland
- Employees
- MPU N/A
- MURA N/A
- Industry
- MPU Transportation Services
- MURA
- Sector
- MPU Consumer Discretionary
- MURA
- Exchange
- MPU Nasdaq
- MURA Nasdaq
- Market Cap
- MPU 51.4M
- MURA 57.2M
- IPO Year
- MPU 1998
- MURA N/A
- Fundamental
- Price
- MPU $1.42
- MURA $4.00
- Analyst Decision
- MPU
- MURA Strong Buy
- Analyst Count
- MPU 0
- MURA 4
- Target Price
- MPU N/A
- MURA $16.00
- AVG Volume (30 Days)
- MPU 192.8K
- MURA 239.2K
- Earning Date
- MPU 11-12-2024
- MURA 11-13-2024
- Dividend Yield
- MPU N/A
- MURA N/A
- EPS Growth
- MPU N/A
- MURA N/A
- EPS
- MPU N/A
- MURA N/A
- Revenue
- MPU $26,001,000.00
- MURA N/A
- Revenue This Year
- MPU N/A
- MURA N/A
- Revenue Next Year
- MPU N/A
- MURA N/A
- P/E Ratio
- MPU N/A
- MURA N/A
- Revenue Growth
- MPU 1444400.00
- MURA N/A
- 52 Week Low
- MPU $0.77
- MURA $2.87
- 52 Week High
- MPU $4.48
- MURA $5.62
- Technical
- Relative Strength Index (RSI)
- MPU 48.44
- MURA 66.06
- Support Level
- MPU $1.15
- MURA $3.55
- Resistance Level
- MPU $1.65
- MURA $4.05
- Average True Range (ATR)
- MPU 0.16
- MURA 0.24
- MACD
- MPU 0.01
- MURA 0.07
- Stochastic Oscillator
- MPU 54.00
- MURA 91.35
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.